Evidence map›Paper›PMID 29423619›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Smoking is not associated with higher prevalence of JC virus in MS patients.

Michael Auer, Gabriel Bsteh, Harald Hegen, Franziska Di Pauli, Sebastian Wurth, Thomas Berger, Florian Deisenhammer

Open access · hybridAbstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Anti-JCV antibody index seroconversion in Turkish multiple sclerosis patients treated with natalizumab.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Michael AuerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria. michael.auer@i-med.ac.at.ORCID http://orcid.org/0000-0002-5117-4225
Gabriel BstehDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Harald HegenDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Franziska Di PauliDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Sebastian WurthDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Thomas BergerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Florian DeisenhammerDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Innsbruck Medical University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

John Cunningham virus (JCV) causes rare, but potentially life-threatening progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients. Beside JCV index, there is currently no other factor for further risk stratification. Because smoking was reported as potential risk factor for several viral and bacterial infections, we aimed to investigate whether smoking could increase the risk for JCV infection in MS patients. We screened our database of the MS Clinic of the Department of Neurology, Medical University of Innsbruck, Austria, for patients with known smoking status and test result for anti-JCV antibody index as determined by two-step ELISA at Unilabs, Copenhagen, Denmark. In a representative cohort of 200 MS patients with a rate of 36% current smokers plus 6% former smokers, we were not able to detect any association between smoking and JCV status. Furthermore, there was no association between smoking status and anti-JCV antibody index. Smoking does not seem to be a risk factor for JCV infection in MS patients and, therefore, does not represent a suitable marker for PML-risk stratification under treatment with natalizumab.

Indexed as

JC VirusSmokingAdolescentAdultAustriaFemaleHumansImmunologic FactorsLeukoencephalopathy, Progressive MultifocalMaleMiddle AgedMultiple SclerosisNatalizumabPrevalenceRetrospective StudiesRisk FactorsImmunologic FactorsNatalizumabJCVMultiple sclerosisNatalizumabProgressive multifocal leukoencephalopathySmoking

Identifiers

PMID29423619
PMCPMC5916978
OpenAlexW2793051419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.